| | Parameters | | Result |
| | Age | Years | 71.5 (21.94)b |
| | Sex | Female | 21 (29.2%) | | Male | 51 (70.8%) |
| | Country | Spain | 23 (31.9%) | | USA | 20 (27.8%) | | France | 8 (11.1%) | | Turkey | 5 (6.9%) | | Austria | 4 (5.6%) | | India | 4 (5.6%) | | Indonesia, Korea, Portugal, Brazil, Qatar, Tunisia, Canada, China | 1 (1.4%) |
| | Medical history | Ischemic heart disease | 23 (31.9%) | | Atrial fibrillation | 15 (20.8%) | | Cancer | 15 (20.8%) | | Pulmonary thromboembolism | 13 (18.1%) | | Hypertension | 11 (15.3%) | | Deep vein thrombosis | 10 (13.9%) | | CHF, DM, COPD | 6 (8.3%) | | Hypercholesterolemia, craniocerebral tumor | 4 (5.6%) | | Aortic valve replacement | 3 (4.2%) | | Hypothyroidism, obesity, ESRD, amyloidosis, HIV, cardiomyopathy, ischemic stroke, SVCS hepatitis B/C, chylothorax, lepromatous leprosy, UC, BPH, GCA, KT, SHPT, PH, PAH, bullous pemphigoid, pericarditis, atrial thrombus, occlusion of retinal arteries | 2 (2.8%) | | 1 (1.4%) |
| | Concurrent medications (37)a | Antiplatelet drugs/anticoagulant drug | 28 (38.9%) | | Statins | 7 (9.7%) | | Steroids, nitrate esters, ACEI | 5 (6.9%) | | Diuretic, amiodarone, hypoglycemic drugs | 4 (5.6%) | | PPI, beta receptor blocker | 3 (4.2%) | | Diltiazem, paracetamol, codeine | 2 (2.8%) | | Levetiracetam, eplerenone, mexiletine, metolazone, daratumumab, trimetazidine, escitalopram, ceftazidime, etizolam, levocarnitine, emtricitabine, tenofovir, efavirenz, buflomedil, tamsolusin, voriconazole, calcitonin, hydralazine, levothyroxine, venlafaxine, escitalopram, thyroxin, amoxycillin-clavulanic acid | 1 (1.4%) |
| | Indication | Treatment | 48 (66.7%) | | Prevention | 24 (24.3%) |
|
|
ACEI, angiotensin-converting enzyme inhibitor; AT, atrial thrombus; BPH, benign prostatic hyperplasia; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; ESRD, end-stage renal disease; GCA, giant cell arteritis; HIV, human immunodeficiency virus; KT, kidney transplantation; SHPT, secondary hyperparathyroidism; PH, portal hypertension; PAH, pulmonary artery hypertension; SVCS, superior vena cava syndrome; UC, ulcerative colitis. aRepresents the number of patients out of the 72 who had information available for this particular parameter. bMedian (minimum-maximum).
|
